it was a necessity. how else do they ramp up manufacturing for Excellagen and Excellarate? they are about to take over the DFU market, which is around $1.4+ billion.
sure it could have been more favorable for the o/s. i would have been more comfortable with each Unit being only 5 shares of common stock as opposed to 10.
but i think they will deliver and approval seems pretty likely(~95%). remember this is a 510(k). i think it is a great deal given it is such low risk. we dont have to worry about side effects and whether efficacy was shown, like with oncology. it was a 55% improvement over the standard care.
News 
Market Data 
Discover 
AI
